Narcolepsy presents one of the tightest associations with a specific HLA antigen (DQB1*0602) but there is strong evidence that non-HLA genes also confer susceptibility. Recent observations have implicated the hypocretin/orexin system in narcolepsy in both humans and animals. In addition, the implication of monoaminergic systems in the pathophysiology of narcolepsy is well established and a significant association between the monoamine oxydase-A (MAO-A) gene and human narcolepsy has recently provided a possible genetic link. We investigated polymorphisms of MAO-A and catechol-O-methyltransferase (COMT) in 97 Caucasians with well-defined narcolepsy-cataplexy and sought for genotypic effects on disease symptoms. No evidence of association between genotype or allele frequencies of both MAO-A or COMT gene and narcolepsy was found. However, a sexual dimorphism and a strong effect of COMT genotype on disease severity were found. Women narcoleptics with high COMT activity fell asleep twice as fast as those with low COMT activity during the multiple sleep latency test (MSLT) while the opposite was true for men. COMT genotype also strongly affected the presence of sleep paralysis and the number of REM sleep onsets during the MSLT. In agreement with welldocumented pharmacological results in canine narcolepsy, this study reports the first genetic evidence for the critical involvement of the dopaminergic and/or noradrenergic systems in human narcolepsy. Molecular Psychiatry (2001) 6, 367-372.
Narcolepsy in both humans and animals is a disabling disorder characterized by excessive daytime sleepiness and abnormal rapid-eye-movement (REM) sleep manifestations. 1 These include cataplexy, sleep paralysis, hypnagogic hallucinations, and sleep onset REM periods (SOREMPs). 1 Although narcolepsy is known as a distinct clinical entity for more than a century, 2 only recently a major discovery was made that may shed light on its pathophysiology. In a natural canine model of narcolepsy, a mutation of the gene encoding the type 2 hypocretin/orexin receptor was found to be responsible for the disease 3 and mice with a null mutation of the prepro-hypocretin/-orexin gene also show symptoms of narcolepsy. 4 In contrast, human narcolepsy is genetically complex. Over 90% of cases are sporadic and monozygotic twins are usually discordant for narcolepsy indicating that both genetic and environmental factors are involved. 5 Although human narcolepsy presents one of the tightest associations with a specific HLA antigen (DQB1*0602), 6 there is strong evidence that non-HLA genes also confer susceptibility. Five to 10% of sporadic cases do not express the DQB1*0602 allele and several familial cases have been reported where affected subjects do not share any common HLA haplotype suggesting that the DQB1*0602 allele is neither necessary nor sufficient for the development of narcolepsy. 7, 8 Recently a decreased concentration of hypocretin/orexin 1 was found in the cerebrospinal fluid of narcoleptics 9 and the number of hypocretin/orexin neurons in the hypothalamus was found markedly decreased in several post mortem narcoleptic brains. 10, 11 However, since only a single human case with atypical early onset narcolepsy has been found associated with a prepro-hypocretin/ -orexin gene mutation, 10 the possibility that other genetic factors with different pathophysiological mechanisms are involved cannot be ruled out. Accordingly, reported positive associations with monoamine oxydase-A (MAO-A) 12 and tumor necrosis factor alpha 13 (TNF-alpha) genes may indicate that in addition or independent of the HLA and/or the hypocretin/orexin systems, other susceptibility genes can be found. The implication of monoaminergic systems in the pathophysiology of narcolepsy is established. Studies in canine and human narcolepsy indicated increased density of alpha-1b receptors in the amygdala and of alpha-2 receptors in the locus coeruleus. [14] [15] [16] Also noradrenergic alpha-1 receptor antagonists induce canine cataplexy whereas cataplexy is inhibited by alpha-1 agonists. 17 Finally, current treatments of human narcolepsy depend on central monoamine stimulants such as modafinil or methylphenidate for excessive daytime sleepiness and on tricyclic antidepressants for cataplexy. 17 MAO-A and B selective inhibitors also reduce all REM-sleep-associated symptoms in narcolepsy. 17 Based on abnormal REM sleep symptoms suggestive of narcolepsy in Norrie disease, Koch et al 12 have studied markers in the Norrie disease region on chromosome X of 28 narcoleptic subjects and found a positive association with an intronic variable number of tandem repeat (VNTR) in the MAO-A gene. The confirmation of this finding would constitute the first genetic evidence for the critical involvement of the monoaminergic neurotransmission defect in narcolepsy. Thus, a case-control and a family-based association study were conducted in a large population. In addition we studied another key enzyme of the monoaminergic neurotransmission, the catechol-O-methyltransferase (COMT), and looked for MAO-A and COMT genotype effects on disease symptoms.
MAO-A
No association was found between genotype or allele frequencies of the MAO-A gene and narcolepsy (Table  1 
COMT
No association was found between either the genotype or the allele frequencies of the COMT gene and narcolepsy. However, genotype distribution appeared different between men and women narcoleptics ( 2 = 5.85, df 2, P = 0.05). The difference was due to the even number of women with either genotype while a lower number of men narcoleptics had the LL genotype (LL vs LH Table 1 MAO-A RFLP, MAO-A VNTR and COMT RFLP allele or genotype distribution in narcoleptics and controls .84, df 2, P Ͻ 0.003), the latency to sleep at night (ANOVA, F 2,67 = 3.9, P Ͻ 0.03; LL = 8.2 ± 2.9 min, LH = 4.9 ± 1.2 min, HH = 13.9 ± 4.1; LH vs HH P Ͻ 0.05 post-hoc t-test), and the number of SOREMPs during the multiple sleep latency test (MSLT) (ANOVA, F 2,72 = 6.2, P Ͻ 0.004; LH vs LL or HH P Ͻ 0.05 post-hoc t-test). COMT heterozygous genotype was significantly associated with a higher number of patients with sleep paralysis but with a lower number of SOREMPs (Figure 1 ). More interestingly, 2-way ANOVA on mean sleep latencies during the MSLT showed a significant gender and COMT genotype interaction (F 2,72 = 3.8, P Ͻ 0.03). The MSLT scores are reported in Table 2 where a clear opposite effect of the COMT genotype is evident. Women narcoleptics with LL and LH genotypes have an MSLT score twice as long as those with the HH genotype while the opposite is true for men. Finally, no interaction was found between COMT and HLA DQB1*0602 genotype in either narcoleptics or controls. 
MAO-A VNTR
Based on the present analysis, we failed to demonstrate any allele or genotype association between narcolepsy and the MAO-A gene polymorphism. Monoamine oxidases are flavin-containing enzymes that degrade a variety of biogenic amines, including the neurotransmitters dopamine, epinephrine, norepinephrine, and serotonin. The two forms of the enzyme MAO-A and MAO-B, are encoded by two adjacent genes located at the p11.23-11.4 region on chromosome X. MAO-A activity is under strong genetic control and accounts for more than 80% of MAO activity. 18 
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Variation in MAO activity affects behavioral traits in humans [19] [20] [21] and animals 22 thought to be mostly related to the serotonergic neurotransmission.
In contrast to our data, Koch et al 12 reported a positive association between MAO-A and narcolepsy. The discrepancy between the two studies could result from several differences between the investigated populations. First, the number of narcoleptics in Koch et al 12 (28 patients) and the proportion of HLA DR2-negative subjects (28.6% of patients) are probably not representative of the narcolepsy population. Second, despite the fact that the analysis concerned an X-located gene, the gender in their analysis was not taken into account and the men to women ratio in patients and controls was different.
None of the many clinical and laboratory data used in the present study were found to be affected by the functional MAO-A gene variant, suggesting a minor or nonexistent role for this system in the pathophysiology of narcolepsy.
Although there was no association between narcolepsy and the COMT gene polymorphism, striking gene effects on disease severity could be evidenced. COMT is a Mg 2+ -dependent enzyme widely distributed in the brain and periphery that catalyzes the transfer of a methyl group from S-adenosylmethionine to catecholamines, including the neurotransmitters dopamine, epinephrine, and norepinephrine. This Omethylation results in one of the major degradative pathways of the catecholamines and the relative importance of COMT vs MAO-A activity varies in different brain regions. Since COMT has a crucial role in the metabolism of dopamine, it was suggested that a common functional genetic polymorphism in the COMT gene, which results in 3-to 4-fold difference in COMT enzyme activity, might contribute to the etiology of many neuropsychiatric disorders. 23, 24 The present study reports for the first time a sexual dimorphism in COMT activity in human narcolepsy, the mechanism of which remains to be defined. A similar pattern in COMT activity has been described previously for genetic susceptibility to obsessive-compulsive disorder in humans 24 and to aggressive behavior in mice. 25 We also showed that highly significant differences in disease severity (mostly related to excessive daytime sleepiness) can be evidenced in association with the COMT genotypes suggesting, as already welldocumented in canine narcolepsy, that abnormalities in the dopaminergic/noradrenergic neurotransmission are critically involved in the pathophysiology of narcolepsy. However, since this finding seems independent from direct implication of the COMT gene in narcolepsy, similar data in normal and sleep-disordered populations might be necessary to verify and extend these findings. It is also not clear how COMT activity affects different symptoms in narcolepsy since, for instance, the number of SOREMPs and the MSLT scores do not follow the same COMT genotype distribution. Severity of narcolepsy is not easy to determine; excessive daytime sleepiness and frequency of cataplexy should represent the most severe symptoms reported by the patients while the number of SOREMPs is not always a consistent finding and may not be related to the severity of narcolepsy. 1 Additionally, we have already reported that both sleep latencies and the number of SOREMPs differ markedly between all-night (or continuous) PSG recordings and the standard MSLT, with overestimation of these parameters by the MSLT. 26 The severity of cataplexy was assessed by using a scale from 1 to 5 according to its frequency (see Methods). This procedure might have influenced the outcome of our analysis: failing to find a significant association with the investigated polymorphism, whereas sleep paralysis was assessed as present or absent and showed a highly significant association. The finding that a higher number of patients with sleep paralysis and a lower number of SOREMPs are heterozygous COMT instead of either homozygous genotype may also appear surprising. This nonmonotonic gene dosage effect has been observed in heterozygous COMT 25 and ␣-calcium-calmoduline kinase II mutant mice for aggressive behavior 27 and does not seem to have a simple explanation. As in the mouse model, one explanation may assume that in heterozygous subjects, half gene dosage is unable to induce compensatory processes while either homozygous genotypes bring COMT activity below or above a threshold and induce compensatory processes. Finally, a number of brain regions may be involved in different symptoms and regional brain COMT activity, which is unknown, may differ markedly.
Since no association was found between COMT and HLA (DQB1*0602) genotypes, the presence of another narcolepsy susceptibility gene that may link dopaminergic and/or noradrenergic systems to narcolepsy syndrome can be suspected. One such candidate gene may be found in the hypocretin/orexin system recently discovered to be critically involved in narcolepsy. [9] [10] [11] The hypocretin/orexin-containing neurons are only found in a restricted region of the hypothalamus but send extensive projections to many brain regions especially to the dopaminergic and noradrenergic systems in the mesopontine junction. 28 It is suggested that hypocretinergic/orexinergic input to these systems is excitatory and should increase dopamine/ norepinephrine tone thereby promoting vigilance. 29 In narcolepsy, a defect in hypocretin/orexin innervation of these targets would induce a hypoactivity of the monoaminergic systems as compared to the cholinergic systems, which results in an imbalance between the two systems. 29 Thus it can be hypothesized that the hypoactivity of the monoaminergic systems in narcolepsy may also involve a hypocretin/orexin-COMT gene interaction.
A recent study on human familial narcolepsy reported a suggestive linkage to chromosome 4p13-q21, a region that contains the circadian locomotor output cycles kaput (CLOCK) gene and the ␥-aminobutyric acid receptor ␤-1 (GABRB1) gene. 30 Possible interactions of functional polymorphisms of these genes and the dopaminergic and/or noradrenergic systems also need further investigation.
In conclusion, narcolepsy is a genetically complex disorder. Our results confirm that dopaminergic/ noradrenergic systems are more critically involved than serotonergic systems in human narcolepsy. This finding represents the first genetic evidence in human narcolepsy for the well-documented pharmacological data on monoaminergic systems available from the canine model.
Methods

Patients
Ninety-seven French Caucasian patients (59 men and 38 women) with typical narcolepsy (ie recurrent daytime sleep episodes and well-defined cataplexy) were included. Ten narcoleptics have a positive familial history of narcolepsy (five men and five women) and 90 were HLA DQB1*0602 positive. Most (n = 73) underwent a nocturnal polysomnography (PSG) followed, the next day, by the MSLT, which confirmed the diagnosis with the presence of at least two SOREMPs and the MSLT score of less than 8 min. Among these patients, 68 had received the narcolepsy diagnosis for the first time and were therefore drug-naïve while the five others were unmedicated for at least 3 weeks and PSG evaluations did not indicate any sign of REM sleep and/or REM-related symptom rebound. Age of onset of narcolepsy was established on the basis of the clinical investigation made at the time of the initial examination and represents the age of occurrence of the first symptoms of narcolepsy, either excessive daytime sleepiness (EDS) or cataplexy or both. The mean duration of symptoms (from the onset to the diagnosis) was 13.3 years (range from Ͻ1 to 50 years). Other available information was the age at time of diagnosis, the frequency of cataplectic attacks on a scale from 1 to 5, where 1 represents one or less cataplectic attack per year; 2, more than one cataplectic attack per year but less than one per month; 3, more than one attack per month but less than one per week; 4, more than one per week but less than one per day; and 5, severe cases with at least one cataplectic attack per day. Other information included the presence or absence of hypnagogic hallucinations and sleep paralysis since the onset of the disease as well as the presence or otherwise of a positive family history of narcolepsy.
One hundred and twenty-one ethnically matched (72 men and 49 women) including 17 HLA DQB1*0602-positive subjects were included as controls.
Fresh blood samples were collected from all subjects and genomic DNA was isolated by standard protocols. In 40 narcolepsy cases (13 women and 27 men), DNAs from both (28 cases) or one of the parents (12 cases) were also obtained to investigate the homogeneity of transmission disequilibrium between men and women probands and to compare allele transmission from heterozygous parents to affected children. In two female cases the mother was affected either with typical narcolepsy or with EDS without cataplexy.
Genotyping MAO-A (Xp11.23) genotypes were determined at two polymorphic sites: a T-to-G substitution at codon 297/exon 8, which results in a Fnu4H1 restriction site with two alleles (H: 65 bp, L: 130 bp); and the VNTR/intron 1 (as reported by Koch et al 12 ) with different alleles grouped as short or long. The target sequences were PCR amplified and the products were either digested by the restriction enzyme Fnu4H1 and electrophoresed in a 2% agarose gel or electrophoresed in a 5% polyacrylamide sequencing gel to detect the size of the VNTR. The RFLP polymorphism has been associated with high MAO-A activity in vitro when the Fnu4H1 site is present. 18 COMT (22q11.2) genotypes were determined by RFLP analysis. A G to A substitution at codon 158 encoding a valine or methionine generates the polymorphism. The target sequence was PCR amplified and the product was digested by the restriction enzyme NlaIII and electrophoresed in a 8% polyacrylamide gel to detect the two alleles (Met158 or L for low activity 64-bp allele vs Val158 or H for high activity 91-bp allele). This polymorphism is functionally relevant since the LL genotype corresponds to three to four times less activity of the enzyme as compared to the HH genotype. 23 
Statistical analysis
Genotype and allele frequencies were compared between narcoleptic and control groups, and between gender by means of 2 and Fisher's exact probability test. A two-way analysis of variance (ANOVA) was used to assess the effects of genotype and gender on clinical and PSG data in the narcolepsy group. The clinical variables (age of onset, score on the Epworth sleepiness scale, frequency of cataplexy, hypnagogic hallucinations, sleep paralysis, positive family history of narcolepsy) and PSG variables (sleep latency, REM latency, total sleep time, sleep efficiency, REM efficiency, number of awakenings, score and number of SOREMPs on MSLT) were considered in the analysis.
